Delivery Order SPE2DB22D2007-SPE2DB25FJ3XZ
Award Date 8/13/25
Potential Completion Date 8/14/25
Potential Value $6.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $5,909.37 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose, 10 count packages) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside award and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is an acute migraine treatment medication, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $3,392.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor...
- The Defense Logistics Agency awarded a $5,423.70 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-unit dose packages) with a completion deadline of September 2, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,427.25 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packs (16 count). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 25, 2025. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for acute migraine treatment. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of UBRELVY (ubrogepant) 50 mg tablets in unit dose packaging of 10 tablets each, with a ceiling value of $3,085.51. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, executed under a competitive, non-set-aside procurement process. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging on July 29, 2025, with a ceiling value of $2,706.94 and ultimate completion date of July 30, 2025. UBRELVY is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment. This delivery order was competitively awarded without set-aside designation and carries firm fixed pricing. The contract is performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,514.77 for UBRELVY 50 mg tablets (UD 10s) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is an acute migraine treatment medication, representing one of numerous pharmaceutical products supplied...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...